Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained immunotolerance in multiple sclerosis after stem cell transplant.
Visweswaran M, Hendrawan K, Massey JC, Khoo ML, Ford CD, Zaunders JJ, Withers B, Sutton IJ, Ma DDF, Moore JJ. Visweswaran M, et al. Among authors: hendrawan k. Ann Clin Transl Neurol. 2022 Feb;9(2):206-220. doi: 10.1002/acn3.51510. Epub 2022 Feb 1. Ann Clin Transl Neurol. 2022. PMID: 35106961 Free PMC article. Clinical Trial.
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ, Ma DDF. Moore JJ, et al. Among authors: hendrawan k. J Neurol Neurosurg Psychiatry. 2019 May;90(5):514-521. doi: 10.1136/jnnp-2018-319446. Epub 2018 Dec 11. J Neurol Neurosurg Psychiatry. 2019. PMID: 30538138 Clinical Trial.
Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis.
Massey J, Jackson K, Singh M, Hughes B, Withers B, Ford C, Khoo M, Hendrawan K, Zaunders J, Charmeteau-De Muylder B, Cheynier R, Luciani F, Ma D, Moore J, Sutton I. Massey J, et al. Among authors: hendrawan k. Front Immunol. 2022 Feb 7;13:798300. doi: 10.3389/fimmu.2022.798300. eCollection 2022. Front Immunol. 2022. PMID: 35197974 Free PMC article.
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Cullen JK, Yap PY, Ferguson B, Bruce ZC, Koyama M, Handoko H, Hendrawan K, Simmons JL, Brooks KM, Johns J, Wilson ES, de Souza MMA, Broit N, Stewart P, Shelley D, McMahon T, Ogbourne SM, Nguyen TH, Lim YC, Pagani A, Appendino G, Gordon VA, Reddell PW, Boyle GM, Parsons PG. Cullen JK, et al. Among authors: hendrawan k. J Immunother Cancer. 2024 Apr 24;12(4):e006602. doi: 10.1136/jitc-2022-006602. J Immunother Cancer. 2024. PMID: 38658031 Free PMC article.